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ABSTRACT

Objective: To describe the clinical features of a novel fused in sarcoma (FUS) mutation in a young
adult female amyotrophic lateral sclerosis (ALS) patient with rapid progression of weakness and
to experimentally validate the consequences of the P525R mutation in cellular neuronal models.
Methods: We conducted sequencing of genomic DNA from the index patient and her family members. Immunocytochemistry was performed in various cellular models to determine whether the
newly identified P525R mutant FUS protein accumulated in cytoplasmic inclusions. Clinical features of the index patient were compared with 19 other patients with ALS carrying the P525L
mutation in the same amino acid position.
Results: A novel mutation c.1574C.G (p.525P.R) in the FUS gene was identified in the index
patient. The clinical symptoms are similar to those in familial ALS patients with the P525L
mutation at the same position. The P525R mutant FUS protein showed cytoplasmic localization
and formed large stress granule–like cytoplasmic inclusions in multiple cellular models.

Conclusions: The clinical features of the patient and the cytoplasmic inclusions of the P525R
mutant FUS protein strengthen the notion that mutations at position 525 of the FUS protein
result in a coherent phenotype characterized by juvenile or young adult onset, rapid progression,
variable positive family history, and female preponderance. Neurol Genet 2017;3:e172; doi:
10.1212/NXG.0000000000000172
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; EGFP 5 enhanced green fluorescent protein; fALS 5 familial amyotrophic lateral
sclerosis; FTD 5 frontotemporal dementia; FUS 5 fused in sarcoma; MND 5 motor neuron disease; NLS 5 nuclear localization sequence; PBS 5 phosphate-buffered saline; WT 5 wild type.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the upper and lower
motor neurons of the brain and spinal cord. It causes progressive paralysis and finally death due
to respiratory failure typically within 3 years of symptom onset. Approximately 10%–15% of
the ALS cases are familial ALS (fALS) and caused by mutations in several different genes.
Recently, mutations in the fused in sarcoma (FUS) gene have been identified in a subset of
patients with fALS.1,2 The FUS gene is located on chromosome 16p11.2 and encodes a multidomain protein with 526 amino acids. The FUS protein is predominantly localized in the
nucleus in most tissues, whereas it also has a notable cytoplasmic presence in neurons.3 Most
fALS mutations are located in the C-terminal nuclear localization sequence (NLS),4 causing
accumulation of FUS-containing inclusions in the cytoplasm. The FUS protein binds to RNA/
DNA and is involved in a variety of RNA metabolism pathways, including transcription,5–8
splicing,8–10 nucleocytoplasmic RNA shuttling11 and RNA transport,12 mitochondrial RNA
biogenesis and function,13,14 and DNA repair.15,16
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In this study, we report a novel mutation
c.1574C.G (p.525P.R) in FUS in a 26year-old woman with rapid onset and progression of weakness. The P525R mutant FUS
protein showed cytoplasmic localization and
formed large stress granule–like cytoplasmic
inclusions in multiple cellular models. The
phenotype is similar to fALS individuals with
the p.525P.L mutation, suggesting that
mutations at position 525 in FUS cause fulminant motor neuron disease (MND).

Figure 1

Identification of the P525R mutation and patient pedigree

METHODS Patient information. The index patient was
a 26-year-old woman who experienced subacute onset of proximal upper extremity weakness over 4–6 weeks followed by progression. By 5 months, she had evidence of acute and chronic
denervation on EMG testing in the upper extremities, lower
extremities, thoracic paraspinous, and sternocleidomastoid muscles. The forced vital capacity was 64% of predicted; the following
were normal/negative: comprehensive metabolic panel, complete
blood count, vitamin B12, hemoglobin A1C, heavy metals, creatine kinase, aldolase, Lyme, rapid plasma reagin, antinuclear
antibody, rheumatoid factor, SSa/SSb, serum protein electrophoresis, and HIV. She was evaluated for a second opinion
(M.B.) at 6 months when her ALSFRSr score was 37/48. She was
started on riluzole 50 mg bid.
By 9 months, she was receiving total care in a nursing home.
Her ALSFRSr score was 24/48. On examination, she had bifacial
weakness, normal tongue contour and power, and extensive
weakness of neck flexion and extension. An obese body habitus
with extremity edema precluded evaluation of muscle atrophy
or fasciculations. She did not have antigravity power in any upper
extremity muscle and profound proximal lower extremity weakness. There was muscle hypotonia in the upper extremities and
increased tone in the lower extremities with elevated tendon reflexes and bilateral Babinski signs. She died of respiratory weakness after a 12-month course.
Additional history revealed that her mother was evaluated 12
years back for upper motor neuron predominant ALS (E.J.K.).
By 8 months after the onset of progressive weakness, she had grade
3/5 power in the upper extremities, grade 42/5 power in the lower
extremities, normal bulbar function, and corticospinal tract findings
in extremities and in the bulbar region. Detailed clinical sensory
testing was normal. EMG testing demonstrated fasciculations, few
fibrillations, and large amplitude polyphasic motor unit potentials.
She died at the age of 40 after a 6-year progressive course.

Standard protocol approvals, registrations, and patient
consents. The study was approved by the Institutional Review
Board of the University of Kentucky. Written informed consent
was obtained from all subjects who participated in the study.

Mutation analysis (genomic DNA sequencing). Genomic
DNA was extracted from peripheral blood using the Gentra Puregene Blood Kit (158467; Qiagen, Hilden, Germany). Mutation
analysis on FUS was performed by amplifying the exon encoding
position P525 and its flanking regions, followed by PCR product
sequencing.
Plasmids. The enhanced green fluorescent protein (EGFP)
tagged pEGFP-C3-FUS WT, R521G, P525L, and R495X
plasmids were constructed in previous studies.17,18 The P525R
FUS mutant was amplified using PCR and subcloned into the
pEGFP-C3 (Clontech, Mountain View, CA) vector using the
BglII and KpnI sites.

Cell culture and transfection (N2A, primary cortical
neurons, and human skin fibroblasts). Mouse neuroblas-

(A) Sequencing results of amplified patient genomic DNA. The FUS mutation, c.1574C.G
(p.Pro525Arg) was identified in the patient. The antisense strand electropherogram is shown
on the top, and the reading frame depicting the corresponding amino acid substitution is
shown below. The normal genomic DNA was from the unaffected brother of the patient. (B)
The family pedigree of the patient with ALS. Numbers indicate the age at death based on
family history and public records. Predicted protein composition at position 525 of FUS
based on DNA sequencing. ALS 5 amyotrophic lateral sclerosis; FUS 5 fused in sarcoma;
P 5 proline; R 5 arginine.
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toma N2A cells were cultured in Dulbecco’s Modified Eagle
Medium (D5796; Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum, 100 unit/mL penicillin, and 100 mg/
mL streptomycin in a humidified incubator at 37°C under 5%
CO2/95% air. Transient transfection was performed using Lipofectamine 2000 (Invitrogen, Life Technologies, Grand Island, NY).
Mouse primary cortical neuron cultures were prepared as previously reported.18 Briefly, neonatal mice (strain C57BL/6;
Jackson Laboratory, Bar Harbor, ME) were killed by decapitation
within 24 hours of birth. After the incubation with trypsin, cells

were dissociated using pipette lavage and cultured in Neurobasal
Medium (21103049; Life Technologies) with B27 supplement
(17504044; Life Technologies), L-glutamine, and penicillin/
streptomycin. After the treatment of 5-fluoro-29-deoxyuridine
(F0503; Sigma-Aldrich) for 4 days to kill glial cells, the primary
neurons were transfected with EGFP-tagged WT or mutant FUS
expression plasmids using Lipofectamine 2000 (11668; Life
Technologies). The primary neurons were fixed for immunofluorescence 48 hours after the transfection.
Human skin fibroblast cell cultures were established as previously described.19 Briefly, a 3-mm punch skin biopsy was obtained after informed consent from the patient with
symptomatic ALS and family members who were free of neurologic disease. Skin biopsies were washed with phosphate-buffered
saline (PBS), minced into small pieces, and incubated in a fibroblast growth medium (MEM [M5650; Sigma-Aldrich]

Figure 2

supplemented with 20% fetal bovine serum, 2 mM L-glutamine,
100 unit/mL penicillin, and 100 mg/mL streptomycin) in tissue
culture plates in a humidified incubator at 37°C under 5% CO2/
95% air. Fibroblast cells grew from tissue fragments and were
maintained under the same conditions as above.

Immunofluorescence microscopy. N2A cells or primary cortical neurons were seeded on gelatin or poly-D-lysine hydrobromidecoated glass coverslips. Twenty-four hours after the transfection
with EGFP-FUS, cells were rinsed with 13 PBS, fixed with 4%
formaldehyde in 13 PBS, and permeabilized with 0.25% Triton
X-100 in 13 PBS. Primary fibroblast cells were cultured, fixed, and
permeabilized similarly as above. The primary antibodies used in
this study were mouse anti-FUS (sc-47711; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-G3BP1 (13057-2-AP;
Proteintech), and goat anti-TIA1 (sc-1751; Santa Cruz). The

The P525R mutant FUS is mislocalized in cytoplasmic inclusions in N2A cells

N2A cells were transfected with EGFP-tagged WT or mutant FUS. Cytoplasmic inclusions of mutant FUS were colocalized
with stress granule markers TIA1 and G3BP1 as indicated by arrows. Scale bar, 10 mm. FUS 5 fused in sarcoma; WT 5 wild
type.
Neurology: Genetics
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secondary antibodies were Alexa Fluor 488 donkey anti-mouse
(A-21202; Life Technologies), Alexa Fluor 647 donkey antirabbit (A-31573; Life Technologies), and Alexa Fluor 568 donkey anti-goat (A-11057; Life Technologies). The samples were
mounted using Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA). Images were acquired using a Nikon A1
confocal microscope with a 603 objective.
RESULTS P525R mutation in the index patient. Commercial genetic testing of the ALS patient (Prevention
Genetics, Marshfield, WI) revealed 2 normal alleles in
C9orf72 with 5 and 14 GGGGCC repeats. The
patient was heterozygous in the FUS gene at
c.1574C.G (p.Pro525Arg) and heterozygous for
a predicted benign variant in the SQSTM1 gene c.
C350C.T (p.Ala117Val). Sequencing of 18 additional genes implicated in ALS, frontotemporal
dementia (FTD), and ALS/FTD (i.e., ANG, ARHGEF28, CDH13, CHMP2B, GRN, HNRNPA1,
HNRNPA2B1, MAPT, OPTN, PFN1, PSEN1,
PSEN2, SOD1, TARDBP, TREM2, UBQLN2,
VAPB, and VCP) did not reveal any pathologic

Figure 3

The P525R mutant FUS is mislocalized in cytoplasmic inclusions in
mouse primary cortical neurons

variants. Sequencing results confirmed that the
patient was heterozygous in the FUS gene at
c.1574C.G and that her sibling and maternal grandmother were homozygous for normal alleles in FUS
(figure 1A). DNA was not available from her mother
who died prior to the study. Examination of the pedigree using publicly available records did not identify
any other members with a diagnosis of ALS, MND,
or neurologic impairment (figure 1B).
FUS P525R mutation is mislocalized in cytoplasmic
inclusions in N2A cells and primary cortical neurons.

Because the P525R mutation is located in the NLS
of FUS, we first tested whether this mutation caused
FUS mislocalization in cultured N2A cells compared with other fALS FUS mutants. The wildtype (WT) FUS was located in the nucleus,
whereas the P525R mutant FUS protein mislocalized from the nucleus to the cytoplasm and
formed large inclusions (figure 2). The mislocalization and inclusions are similar to those
observed in P525L and R495X mutations. In
comparison, the R521G mutation also caused
cytoplasmic localization of FUS, but the majority of
the mutant protein was still retained in the nucleus.
In addition, cytoplasmic inclusions of the FUS
P525R mutant colocalized with stress granule
markers G3BP1 and TIA-1 in N2A cells (figure 2).
Similarly, other ALS FUS mutants also showed colocalization of cytoplasmic inclusions and stress granule
markers. The results are consistent with previous
studies that cytoplasmic inclusions of ALS FUS mutants are colocalized with stress granule markers.17,20
We further examined the subcellular localization
of P525R mutant FUS in mouse primary cortical
neurons (figure 3). The P525R mutant FUS protein
was largely localized in the cytoplasm of primary neurons and formed inclusions positive for stress granule
marker G3BP1 in a similar fashion as P525L and
R495X mutants. By contrast, the WT FUS protein
was predominantly in the nucleus. The results from
both N2A and primary neurons consistently indicate
that P525R mutant FUS forms cytoplasmic inclusions reminiscent of stress granules.
Cytoplasmic inclusions of the P525R mutant FUS
protein in human fibroblasts. Skin fibroblast cells derived

Mouse primary cortical neurons were transfected with EGFP-tagged WT or mutant FUS.
Cytoplasmic inclusions of mutant FUS were colocalized with the stress granule marker
G3BP1 as indicated by arrows. Scale bar, 10 mm. FUS 5 fused in sarcoma; WT 5 wild type.
4
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from this patient were examined along with fibroblast
cells from patients with fALS carrying the R521G
mutation or healthy controls. Under normal cell culture conditions, the majority of the mutant FUS protein was still localized in the nucleus with visible
cytoplasmic distribution. Several cytoplasmic puncta
of mutant FUS were observed colocalizing with the
stress granule marker G3BP1 (figure 4A). The partial
mislocalization in patient-derived primary fibroblasts is
similar to the previously published study.19

Figure 4

Mislocalization of the P525R mutant FUS in skin fibroblast cells
derived from the patient with ALS

(A) Relatively a small amount of mutant FUS was mislocalized in the cytoplasm and formed
puncta colocalized with G3BP1 (as indicated by arrows) under normal cell culture conditions.
(B) Skin fibroblast cells were treated with 0.5 mM sodium arsenite for 1 hour before fixation.
Under arsenite (oxidative stress) treatment, a notable amount of FUS P525R mutant mislocalized in the cytoplasm and formed inclusions colocalized with G3BP1. Scale bar, 10 mm.
ALS 5 amyotrophic lateral sclerosis; FUS 5 fused in sarcoma.

To determine the response of WT and different
mutant FUS proteins to stress, we treated fibroblasts
with sodium arsenite that induces oxidative stress. All
fibroblasts responded to arsenite treatment and
formed numerous stress granules in the cytoplasm
as marked by the stress granule marker G3BP1 (figure
4B). However, the P525R mutant FUS protein responded differently from the WT or R521G mutant.
A substantial portion of P525R mutant FUS was
mislocalized into the cytoplasm and colocalized with
G3BP1 in stress granules (figure 4B). By contrast,
WT FUS in healthy control cells and the R521G
mutant FUS in fibroblast cells derived from another

patient with ALS showed little response to the arsenite treatment. The result suggests that fibroblasts
carrying the P525R mutation are more vulnerable
to oxidative stress compared with either the WT or
the R521G mutation.
DISCUSSION Here, we report a patient with ALS
carrying a novel heterozygous FUS mutation P525R
(figure 1). Based on the family history, her mother
also died of ALS, and we speculate that she carried the
FUS P525R mutation. The index patient’s grandmother is healthy in her 70s and has 2 WT FUS
alleles; thus, we speculate that her mother likely
gained a spontaneous mutation at c.1574C.T. We
identified 19 ALS cases carrying the P525L mutation
in the FUS gene in the literature and summarized
them in table. The literature indicates that approximately 70% of ALS subjects with the documented
P525L mutation have no family history of ALS
(table), suggesting that either spontaneous mutation
event at this locus is not infrequent and/or that individuals with ALS do not survive long enough to
reproduce, thus appearing to be sporadic ALS. Previous studies determined that the C-terminal 32
amino acids of FUS functions as an NLS and is critical for its nuclear import mediated by transportin
(Trn1).21–23 Indeed, many ALS FUS mutations are
located in the NLS. Mutations on the very end of
the C-terminus appear to cause the most rapidly progressive phenotype with basophilic cytoplasmic inclusions in motor neurons at autopsy. At the position of
amino acid 525 of FUS, P525L mutation has been
linked to familial ALS and apparently sporadic cases24
(table). Patients with a P525L mutation were found
to have an early disease onset and rapidly progressive
disease with short survival when compared with patients with other FUS mutations.21,24 In this study,
the patient with the P525R mutation also had an
early onset in her mid-20s and a rapid progression
over a 12-month course to death. The clinical features
are similar to those carrying the truncated R495X
mutation lacking the entire NLS (mean age at onset:
35 6 16 years; average survival: 16.4 6 10 months
from disease onset).25 The novel P525R mutation in
this case strengthens the notion that mutations at
position 525 of FUS are more fulminant as compared
to other FUS mutations. There is a female preponderance in the reported patients with P525L FUS
occurring in 75% of recorded cases (table). We currently have no explanation for this phenomenon.
The importance of the C-terminal proline residue
was reported for other NLS in which Pro525 and
Tyr526 are strictly conserved as the signature
PY-NLS.26 Figure 5, which is based on our previously
published structural analysis, shows that P525 plays
a critical role in the binding of FUS-NLS to Trn1
Neurology: Genetics
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Table

ALS patients with a mutation at position P525 of FUS
Clinical involvement

Case

Sex

Age at
onset, y

Survival,
moa

FUS genotype

Protein

Family
history

Ethnicity

Onset

Bulbar

Limb

Lower motor
neuron

Upper motor
neuron

Atypical featuresb

Autopsy

Citation

1

NR

22

6

c.1574C.T

p.P525L

NR

NR

NR

NR

NR

NR

NR

NR

No

Kwiatkowski et al.1

c

Neurology: Genetics

2

F

21

12

c.1574C.T

p.P525L

Yes

White

Bulbar

Yes

Yes

Yes

Yes

No

No

Chio et al.29

3

F

22

10

c.1574C.T

p.P525L

No

White

LEd

No

Yes

Yes

No

No

Yes

Bäumer et al.30;
Mackenzie et al.24

4

F

18

11

c.1574C.T

p.P525L

No

Afrowhite

UE

Yes

Yes

Yes

Yes

No

Yes

Bäumer et al.30;
Mackenzie et al.24

5

F

13

17

c.1574C.T

p.P525L

No

NR

LE

No

Yes

Yes

No

Motor developmental delay;
mild learning disability

Yes

Huang et al.31

6

M

13

24

NR

p.P525L

Yes

Japanese

LE

NR

Yes

NR

NR

No

Yes

Ito et al.32

7

NR

11

NR

NR

p.P525L

Yes

White

NR

NR

NR

NR

NR

No

No

Fecto et al.33

8

NR

44 (?)

NR

c.1574C.T

p.P525L

NR

NR

NR

NR

NR

NR

NR

NR

No

Kwiatkowski et al1

9

NR

15

NR

c.1574C.T

p.P525L

NR

NR

NR

NR

NR

NR

NR

NR

No

Kwiatkowski et al1

e

10

F

13

15

c.1574C.T

p.P525L

Yes

Japanese

Limb

Yes

Yes

NR

NR

Developmental delay

Yes

Mochizuki et al.34

11

M

26

13

c.1574C.T

p.P525L

No

White

Limb

Yes

Yes

Yes

No

No

No

Sporoviero et al.35

12

F

45

42

c.1574C.T; c.521_5231
3delGAGGTG

p.P525L

No

White

Limb

Yes

Yes

Yes

Yes

Previous diagnosis: multiple sclerosis

No

Sporoviero et al.35

13

F

11

14

c.1574C.T

p.P525L

No

NR

Limb

No

Yes

Yes

Yes

No

No

Conte et al.36

14

F

19

NR

c.1574C.T

p.P525L

No

Chinese

Limb

Yes

Yes

Yes

Yes

No

No

Zou et al.37

15

F

18

NR

c.1574C.T

p.P525L

No

NR

Bulbar

Yes

NR

NR

NR

No

No

Hübers et al.38

16

M

20

NR

c.1574C.T

p.P525L

No

NR

Bulbar

Yes

NR

NR

NR

No

No

Hübers et al.38

17

M

24

7

c.1574C.T

p.P525L

No

NR

Bulbar

Yes

NR

NR

NR

No

No

Hübers et al.38

18

F

23

8

c.1574C.Tf

p.P525L

Yesg

NR

NR

No

Yes

Yes

Yes

No

Yes

King et al.39

19

F

21

6

c.1574C.T

p.P525L

No

NR

Bulbar

Yes

Yes

Yes

Yes

Ptosis, opthalmoplegia

No

Leblond et al.40

20

F

26

12

c.1574C.G

p.P525R

Yesg

White

UE

Yes

Yes

Yes

Yes

No

No

This report

Abbreviations: ALS 5 amyotrophic lateral sclerosis; FUS 5 fused in sarcoma.
a
Death or 24 h/d assisted ventilation.
b
Prior to assisted ventilation.
c
ALS: mother, maternal grandfather, maternal uncle; not genotyped.
d
UE, upper extremities; LE, lower extremities; NR, not recorded.
e
ALS: sister, mother; not genotyped.
f
Also: TARDP p.Y374X.
g
ALS: mother; not genotyped.

Figure 5

The binding details of the C-terminus of FUS and Trn1

P525 and Y526 of FUS (cyan) and L419, I457, W460 and D384 of Trn1 are shown in sticks. Trn1 is shown in static electric
surface mode, in which the red, blue, and green represent negative charge, positive charge, and hydrophobicity, respectively. The hydrogen bond between Y526 and D384 is illustrated. (A) WT FUS binding is based on the structure of the
FUS-NLS/Trn1 complex (protein data bank entry 4FQ3). (B) An illustration of the P525R mutant structure. If R525 should
remain in the same position as P525, the side chain of R525 would insert into the surface of Trn1. The steric constrains will
force R525 to adapt a different conformation. Consequently, the Y526 residue (shown in thin sticks) in the P525R mutant
should not keep the same conformation as in the WT structure. FUS 5 fused in sarcoma; NLS 5 nuclear localization
sequence; WT 5 wild type.

through the hydrophobic interaction with L419,
I457, and W460 of Trn1.21 In addition, P525 puts
a C-terminal bend in the peptide and positions Y526
to form a hydrogen bond with D384 of Trn1. In the
modeling structure of P525R, the strong charge of
Arg does not match the hydrophobicity of the cave
formed by L419, I457, and W460 of Trn1. Moreover, the side chain of Arg is predicted to be too
large to fit in the small cavity (figure 5). Thus, not
only the hydrophobic interaction formed by P525
would be destroyed but also the relocation of residue 525 would push Y526 away and break the
hydrogen bond between Y526 and D384. The
modeling analysis is consistent with previous reports that the P525L mutation caused dramatic
decrease in the binding affinity of FUS-NLS to
Trn1,21,22 leading to substantial cytoplasmic
accumulation.
ALS-linked FUS mutants form cytoplasmic inclusions that are colocalized with stress granule markers
in various cell models.25,27 Using induced pluripotent
stem cell–derived motor neurons, Lenzi et al.28 also
showed that ALS mutant FUS was recruited into stress
granules. In this study, we showed that cytoplasmic
inclusions of FUS P525R were dominant in N2A cells
(figure 2) and primary cortical neurons (figure 3).
These inclusions were colocalized with stress granule
markers TIA1 and G3BP1, suggesting that this novel
mutant P525R was also recruited into stress granules.
However, the mislocalization and inclusion formation
were less prominent in fibroblast cells derived from
patients with ALS under normal experimental conditions (figure 4A). It is likely that the heterozygous

mutation and the endogenous expression levels of the
mutant FUS protein contribute to the observation
that the majority of the FUS protein remained in
the nucleus. It is also likely that cell type difference
between fibroblast cells and neurons contributes to
the less prominent mislocalization of mutant FUS in
fibroblast cells. Nevertheless, when exposed to oxidative stress by sodium arsenite treatment, FUS
P525R mutant fibroblasts showed stronger response
with substantial mislocalization and inclusion formation in cytoplasm as compared to WT and
R521G mutants (figure 4B). This supports the
hypothesis that the P525R mutant is more susceptible to stress conditions such as arsenite-induced
oxidative stress.
We identified a novel mutation in the FUS gene
that is associated with an early onset and rapid rate of
disease progression. Mechanistically, the P525R
mutation causes a cytoplasmic localization of the
FUS protein that is prominently colocalized with
stress granules, suggesting that a substantial cytoplasmic mislocalization and a strong association with
stress granules could be an indicator of the degree
of severity in FUS fALS.
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